GlassScriptPhysician profile
Christy Lynn Phillips
NPI 1346533304
$1,725.09
in general payments reported to CMS, 2019-2025
26 companies · $629 in 2025
The $629 reported for 2025 was more than what 79% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $25.69 · 2022: $41.50 · 2023: $186 · 2024: $842 · 2025: $629.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,658.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,657.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $413.60 | 2021-2025 | Airsupra, Breztri, Farxiga |
| Supernus Pharmaceuticals, INC. | $275.09 | 2024-2025 | Qelbree |
| Novo Nordisk INC | $120.58 | 2023-2025 | Wegovy |
| Sanofi Pasteur INC. | $100.10 | 2023-2025 | |
| Abbvie INC. | $94.01 | 2024-2025 | |
| Ironshore Pharmaceuticals INC. | $91.59 | 2023-2024 | Jornay Pm |
| Lilly USA, LLC | $89.90 | 2024-2025 | Zepbound, Jardiance, Mounjaro |
| Pfizer INC. | $75.54 | 2023-2025 | |
| Amgen INC. | $69.61 | 2023-2024 | Otezla, Repatha |
| Abbott Laboratories | $47.47 | 2024-2025 | Freestyle Libre 3 |
| Astellas Pharma US INC | $41.28 | 2024 | Veozah |
| Corium, LLC | $33.22 | 2025 | Azstarys |
| Glaxosmithkline, LLC. | $32.50 | 2021-2024 | Arexvy, Bexsero, Shingrix |
| Phathom Pharmaceuticals, INC. | $32.27 | 2025 | Voquezna |
| Merck Sharp & Dohme LLC | $29.60 | 2025 | Vaxneuvance, Capvaxive, Gardasil 9 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.63 | 2025 | Caplyta |
| Esperion Therapeutics, INC. | $18.40 | 2024 | Nexletol |
| Exact Sciences Corporation | $18.14 | 2025 | The Cologuard Plus Collection Kit |
| Mylan Specialty L.P. | $17.52 | 2023 | Yupelri |
| Corcept Therapeutics | $16.41 | 2025 | Korlym |
| Sumitomo Pharma America, INC. | $15.99 | 2025 | Gemtesa |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.40 | 2024 | Trulance, Xifaxan |
| Collegium Pharmaceutical, INC. | $14.92 | 2025 | Jornay Pm |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.55 | 2025 | Jardiance |
| Paratek Pharmaceuticals, INC. | $13.67 | 2024 | Nuzyra |
| Daiichi Sankyo INC. | $13.10 | 2023 | Injectafer |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christy Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.